News
Bugworks secures funding from US Government's Defense Threat Reduction Agency (DTRA) to validate its clinical asset against the toughest bacterial biothreats
"We are very delighted to collaborate with DTRA and through them get the opportunity of working with intra-government agencies within the United States department of Defense, to advance BWC0977 as a potential single-stop solution against the most critical pathogens implicated in biothreats," added Anand Anandkumar, CEO of Bugworks.
ICMR study shows COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well
Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease
Minister Piyush Goyal launches the Startup India Seed Fund Scheme
Minister says the scheme will Secure seed funding, Inspire innovation, Support transformative ideas, Facilitate implementation, and Start startup revolution. 3,600 startups are expected to benefit from the scheme.
BioEconomy Conclave 2026
